Table 3.
Problems | Possible way to overcome |
---|---|
1) Disease control during the CAR‐T cell production | |
2) Production failure | |
3) Healthy B‐cell depletion; on‐target off‐tumor effect |
|
4) Poor expansion and early elimination of CAR‐T cells |
|
5) Insufficient activity of CAR‐T cells | |
6) CD19 negative conversion | |
7) Optimal management of CRS | |
8) Optimal management of neurologic toxicity |
|
CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CRS, cytokine release syndrome.